Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Kenya has been increasing steadily over the past few years.
Customer preferences: Patients in Kenya who require immunosuppressants are mainly those who have undergone organ transplants or suffer from autoimmune diseases such as lupus and rheumatoid arthritis. These patients require long-term treatment with immunosuppressants to prevent their immune system from attacking their own organs or tissues.
Trends in the market: The market for immunosuppressants in Kenya is being driven by the increasing prevalence of autoimmune diseases and organ failure. The rise in non-communicable diseases such as diabetes, hypertension, and cancer has also contributed to the growth of the market as these diseases can lead to organ failure. Additionally, the increasing availability of immunosuppressants in Kenya has made it easier for patients to access these drugs.
Local special circumstances: One of the challenges facing the immunosuppressants market in Kenya is the high cost of these drugs. Most patients in Kenya have to pay out-of-pocket for their medication, which can be a significant financial burden. This has led to some patients not being able to afford their medication, which can lead to serious health consequences. Another challenge is the lack of awareness among patients and healthcare providers about the proper use of immunosuppressants.
Underlying macroeconomic factors: Kenya's healthcare system is undergoing significant reforms, with a focus on expanding access to healthcare services and improving the quality of care. The government has increased funding for healthcare and is working to strengthen the regulatory framework for drugs. These reforms are expected to support the growth of the immunosuppressants market in Kenya by improving access to healthcare services and increasing awareness about the importance of proper medication use. Additionally, the growth of the pharmaceutical industry in Kenya is expected to lead to increased local production of immunosuppressants, which could help to lower the cost of these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
